JP2022535061A5 - - Google Patents

Info

Publication number
JP2022535061A5
JP2022535061A5 JP2021571687A JP2021571687A JP2022535061A5 JP 2022535061 A5 JP2022535061 A5 JP 2022535061A5 JP 2021571687 A JP2021571687 A JP 2021571687A JP 2021571687 A JP2021571687 A JP 2021571687A JP 2022535061 A5 JP2022535061 A5 JP 2022535061A5
Authority
JP
Japan
Prior art keywords
bispecific
construct according
binding construct
bispecific binding
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535061A (ja
JP7661245B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036464 external-priority patent/WO2020247852A1/en
Publication of JP2022535061A publication Critical patent/JP2022535061A/ja
Publication of JP2022535061A5 publication Critical patent/JP2022535061A5/ja
Application granted granted Critical
Publication of JP7661245B2 publication Critical patent/JP7661245B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571687A 2019-06-07 2020-06-05 二重特異性結合構築物 Active JP7661245B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962858509P 2019-06-07 2019-06-07
US201962858630P 2019-06-07 2019-06-07
US62/858,630 2019-06-07
US62/858,509 2019-06-07
PCT/US2020/036464 WO2020247852A1 (en) 2019-06-07 2020-06-05 Bispecific binding constructs

Publications (3)

Publication Number Publication Date
JP2022535061A JP2022535061A (ja) 2022-08-04
JP2022535061A5 true JP2022535061A5 (cg-RX-API-DMAC7.html) 2023-06-07
JP7661245B2 JP7661245B2 (ja) 2025-04-14

Family

ID=71523197

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021571687A Active JP7661245B2 (ja) 2019-06-07 2020-06-05 二重特異性結合構築物
JP2021571682A Active JP7618592B2 (ja) 2019-06-07 2020-06-05 選択的に切断可能なリンカーを有する二重特異性結合構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021571682A Active JP7618592B2 (ja) 2019-06-07 2020-06-05 選択的に切断可能なリンカーを有する二重特異性結合構築物

Country Status (9)

Country Link
US (2) US20220227888A1 (cg-RX-API-DMAC7.html)
EP (2) EP3980125A1 (cg-RX-API-DMAC7.html)
JP (2) JP7661245B2 (cg-RX-API-DMAC7.html)
CN (3) CN114206942A (cg-RX-API-DMAC7.html)
AU (2) AU2020289474A1 (cg-RX-API-DMAC7.html)
CA (2) CA3142165A1 (cg-RX-API-DMAC7.html)
MA (2) MA56120A (cg-RX-API-DMAC7.html)
MX (2) MX2021014931A (cg-RX-API-DMAC7.html)
WO (2) WO2020247852A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3184351A1 (en) * 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
WO2025199278A2 (en) * 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked multispecific antigen-binding molecules with cleavable linkers
WO2026152120A2 (en) 2025-01-13 2026-07-16 HCW Biologics, Inc. Chimeric polypeptides and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DE19650370A1 (de) 1996-12-05 1998-06-10 Basf Ag Flammwidrige thermoplastische Formmassen auf der Basis von Polyarylenethern
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR100609578B1 (ko) 2004-12-28 2006-08-08 주식회사 하이닉스반도체 플래쉬 메모리소자의 플로팅 게이트전극 형성방법
GB0601513D0 (en) 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
TWI404727B (zh) 2006-01-25 2013-08-11 荷蘭鹿特丹Erasmus大學醫學中心 對偶基因排除
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
CA2682605A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
KR101711222B1 (ko) 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
BR112013002167A2 (pt) * 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
IL282953B2 (en) * 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
EP2938637A2 (en) * 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
LT3027642T (lt) 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
EP3027647A4 (en) 2013-07-31 2017-01-04 Amgen Inc. Stabilization of fc-containing polypeptides
WO2015191934A2 (en) * 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
EP3197916A2 (en) * 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究(慕尼黑)公司 Flt3及cd3抗體構築體
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Dll3及cd3抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究(慕尼黑)公司 Msln及cd3抗體構築體
AR107582A1 (es) * 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
US10617773B2 (en) * 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)

Similar Documents

Publication Publication Date Title
US11999801B2 (en) Multispecific antibodies
JP7591015B2 (ja) 抗体構築物
Brinkmann et al. The making of bispecific antibodies
Plückthun et al. New protein engineering approaches to multivalent and bispecific antibody fragments
Kriangkum et al. Bispecific and bifunctional single chain recombinant antibodies
Müller et al. The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies
EP2361936B1 (en) Antigen-binding molecule and uses thereof
Wu et al. Building blocks for bispecific and trispecific antibodies
AU680685B2 (en) Retargeting antibodies
MX2014000816A (es) Molecula fv de union de antigeno multivalente.
CN112384243A (zh) 三价三特异性抗体构建体
EP4303231A1 (en) Bispecific antibody
TWI690539B (zh) 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用
JP2021512151A5 (cg-RX-API-DMAC7.html)
KR20210107747A (ko) 항체 융합 단백질, 이의 제조 방법 및 이의 적용
JP2025512865A5 (cg-RX-API-DMAC7.html)
CN113646328A (zh) 一种免疫细胞因子及其制备与用途
JP2024507693A5 (cg-RX-API-DMAC7.html)
US20250197481A1 (en) Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
JP2025512953A5 (cg-RX-API-DMAC7.html)
Humphreys et al. F (ab′) 2 molecules made from Escherichia coli produced Fab′ with hinge sequences conferring increased serum survival in an animal model
JP2022535060A5 (cg-RX-API-DMAC7.html)
JP2023511652A (ja) 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用
WO1995008577A1 (en) Retargeting antibodies
JP2026513991A (ja) Steap2指向性t細胞エンゲージャー及びその組成物